We keep reiterating that CAR-T cancer immunotherapy was created to stay. More frequent updates about the CAR-T approach further solidified our conviction. Almost every week we are getting news eliminating layer by layer of the true problems about CAR-T therapy that transplanted skepticism in investors’ minds towards a successful outcome of this novel immunotherapy approach to cancer treatment. The two essential problems that instilled the doubt relate to safety and inefficiency and to the inability of the CAR-T therapy to treating all types of malignancies. Of the safety, the lead problem has been the frequently occurring . . .